Safety and efficacy of FOLFOX plus bevacizumab or FOLFIRI plus bevacizumab as second line Therapy in Advanced colorectal Cancer previously treated with bevacizumab. - JSWOG0901

Japan South West Oncology Group0 个研究点目标入组 45 人开始时间: 2009年8月28日最近更新: 2023年10月17日

试验速览

暂无简介。

•(1) Administering transfusion/hematopoietic factor or antithrombotic drug within 14 days (2) Serious renal complications (3) Serious drug hypersensitivity or a history of drug allergy (4) Peripheral neuropathy (5) Active concomitant malignancy (6) Active infections (7) High blood pressure and diabetic that cannot be controlled (8) symptomatic or asymptomatic but treated heart disease (9) interstitial pnumonitis, pulmonary fibrosis or high-grade pulmonary emphysema (10) Traumatic fracture of unrecovery (11) history of mental disturbances or cerebrovascular accident (12) Fresh hemorrhage from digestive tube, intestines tube paralysis, intestinal obstruction and peptic ulcer (13) Current or previous (within one year) history of GI perforation (14) Pleural effusion, peritoneal fluid and pericardial fluid (15) Symptomatic brain metastasis (16) uncontrolled diarrhea (17) Any surgical treatments including skin-open biopsy, trauma surgery and other more intensive surgery within 4 weeks or aspiration biopsy within one week (18) Anti-platelets therapy (including aspirin and NSAIDS) (19) Need to treatment with atazanavir sulfate (20) Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers (21) bleeding tendency(including hemoptysis) or coagulation disorder (22) Other conditions not suitable for this study

发起方

Japan South West Oncology Group